Nautilus Biotechnology Reports First Quarter 2024 Financial Results

Nautilus Biotechnology Reports First Quarter 2024 Financial Results

Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024.

"We continued to make solid progress against our core development goals in Q1," said Sujal Patel, CEO of Nautilus.   "We remain incredibly focused on increasing the scale, stability, and reproducibility of our consumables, assay, instrument, and software and continue to see meaningful gains along each of those dimensions. We are clear-eyed about what work remains to be done and confident that we have a foundational understanding of what is required to establish a new gold standard for the creation and comprehensive analysis of high-value proteomic data."

First   Quarter   2024   Financial Results

Operating expenses were $21.6 million for the first quarter of 2024, a $3.5 million or 20% increase from $18.1 million for the corresponding prior year period. The increase in operating expenses was driven primarily by an increase in headcount to support ongoing development of our products.

Net loss was $18.7 million for the first quarter of 2024, as compared to a net loss of $15.0 million for the corresponding prior year period.

Cash, cash equivalents, and investments were $247.7 million as of March 31, 2024.

Webcast and Conference Call Information

Nautilus will host a conference call to discuss the first quarter 2024 financial results, business developments and outlook before market open on Wednesday, April 30, 2024 at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio .

About Nautilus Biotechnology, Inc.

With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus' mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus' expectations regarding the company's business operations, financial performance and results of operations; expectations with respect to any revenue timing or projections, expectations with respect to the development required for and the timing of the launch of Nautilus' product platform and full commercial availability, the functionality and performance of Nautilus' product platform, its potential impact on providing proteome access, pharmaceutical development and drug discovery, expanding research horizons, and enabling scientific explorations and discovery, and the present and future capabilities and limitations of emerging proteomics technologies. These statements are based on numerous assumptions concerning the development of Nautilus' products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus' assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus' product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus' scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption "Risk Factors" in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q to be filed for the quarter ended March 31, 2024 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Disclosure Information

Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.

Media Contact
press@nautilus.bio

Investor Contact
investorrelations@nautilus.bio

Nautilus Biotechnology, Inc.
Condensed Consolidated Balance Sheets
  As of March 31, 2024 and December 31, 2023 (Unaudited)
(in thousands, except share and per share amounts) March 31, 2024 December 31, 2023
Assets
Current assets:
Cash and cash equivalents $ 25,729 $ 19,397
Short-term investments 155,637 154,021
Prepaid expenses and other current assets 3,728 3,419
Total current assets 185,094 176,837
Property and equipment, net 4,525 4,267
Operating lease right-of-use assets 31,559 32,634
Long-term investments 66,292 90,647
Other long-term assets 1,180 1,180
Total assets $ 288,650 $ 305,565
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 1,860 $ 1,639
Accrued expenses and other liabilities 3,677 3,945
Current portion of operating lease liabilities 3,675 3,538
Total current liabilities 9,212 9,122
Operating lease liabilities, net of current portion 29,946 31,090
Total liabilities 39,158 40,212
Stockholders' equity:
Preferred stock
Common stock 13 13
Additional paid-in capital 471,193 467,834
Accumulated other comprehensive income (loss) (745 ) (255 )
Accumulated deficit (220,969 ) (202,239 )
Total stockholders' equity 249,492 265,353
Total liabilities and stockholders' equity $ 288,650 $ 305,565


Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Operations
  Three Months Ended March 31, 2024 and 2023 (Unaudited)
Three Months Ended March 31,
(in thousands, except share and per share data) 2024 2023
Operating expenses
Research and development $ 12,930 $ 10,877
General and administrative 8,677 7,183
Total operating expenses 21,607 18,060
Other income (expense)
Interest income 2,877 3,098
Other expense (3 )
Total other income $ 2,877 $ 3,095
Net loss $ (18,730 ) $ (14,965 )
Net loss per share attributable to common stockholders, basic and diluted $ (0.15 ) $ (0.12 )
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 125,135,451 124,590,351


Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Cash Flows
  Three Months Ended March 31, 2024 and 2023 (Unaudited)
Three Months Ended March 31,
(in thousands) 2024 2023
Cash flows from operating activities
Net loss $ (18,730 ) $ (14,965 )
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense 3,114 2,860
Amortization of operating lease right-of-use assets 1,075 786
Depreciation 516 385
Amortization (accretion) of premium (discount) on securities, net (751 ) (669 )
Changes in operating assets and liabilities:
Prepaid expenses and other assets (309 ) (513 )
Accounts payable 94 53
Accrued expenses and other liabilities (268 ) 65
Operating lease liabilities (1,007 ) (526 )
Net cash used in operating activities (16,266 ) (12,524 )
Cash flows from investing activities
Proceeds from maturities of securities 23,000 14,249
Purchases of securities (27,052 )
Purchases of property and equipment (647 ) (692 )
Net cash provided by (used in) investing activities 22,353 (13,495 )
Cash flows from financing activities
Proceeds from exercise of stock options 245 1
Net cash provided by financing activities 245 1
Net increase (decrease) in cash, cash equivalents and restricted cash 6,332 (26,018 )
Cash, cash equivalents and restricted cash at beginning of period 20,399 115,477
Cash, cash equivalents and restricted cash at end of period $ 26,731 $ 89,459

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

NAUT
The Conversation (0)
Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Goldman Sachs 45th Annual Healthcare Conference.

Nautilus' management is scheduled to participate in a fireside chat on Monday, June 10, 2024, at 8:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.nautilus.bio .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on March 31, 2025.

Two individuals were hired by Adicet in March 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 38,600 shares of Adicet's common stock with an exercise price of $0.76 per share, the closing price of Adicet's common stock as reported by Nasdaq on March 31, 2025. One-fourth of the shares underlying each employee's option will vest on the one-year anniversary of each recipient's start date and thereafter the remaining three-fourths of the shares underlying each employee's option will vest in thirty-six substantially equal monthly installments, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the recipient's start date, in each case, subject to each such employee's continued employment with Adicet on such vesting dates.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
AbbVie to Host First-Quarter 2025 Earnings Conference Call

AbbVie to Host First-Quarter 2025 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025 before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be available later that day.

About AbbVie

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025.

Details of the event are as follows:
Panel: "CAR T Approaches in the Autoimmune Space"
Date: Monday, April 7, 2025
Time: 3:00 p.m. ET

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Issues Open Letter to Atea's Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers

Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

  • Four expert-led educational events with Allergan Medical Institute (AMI), Science of Aging TM and Allergan Aesthetics (AA) Global Medical Affairs
  • AMI symposia will focus on a new Allergan Aesthetics (AA) Signature Program and celebrate 10 years of MD Codes™, with live injection sessions and fireside chat with world-renowned plastic surgeon Dr. Maurício de Maio
  • Eleven E-Poster data presentations and Meet the Expert sessions with Global experts live from the Allergan Aesthetics booth

Allergan Aesthetics, an AbbVie company, the industry leader in aesthetics globally, demonstrates how to elevate the patient experience and achieve optimal treatment outcomes with new AA Signature program at the Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from Thursday, March 27Saturday, March 29, 2025 .

Activities will center around the new AA Signature program - an innovative approach to treatment planning harnessing the power of Allergan Aesthetics advanced portfolio to address different patient needs, including Lift, Definition and Skin Quality , and a celebration of 10 years of MD Codes™, which has revolutionized aesthetic medicine with innovative methodology to guide injectors' technique and elevate patient outcomes.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Bcal Diagnostics Limited

BCAL Diagnostics Launches BREASTEST plus - Generating First Revenues

BCAL Diagnostics Limited (ASX: BDX) (“BCAL” or “the Company”), an Australian and US-based biotechnology company pioneering non-invasive breast cancer diagnostics, is pleased to announce the commercial launch of BREASTEST plus. This first-in-class blood test is available from Thursday, 27 March 2025 and will be used alongside standard-of-care imaging in breast cancer screening and diagnostics. The Company is pleased that this launch has been achieved within the previously announced target timeframe of having the test commercially available in Australia by the end of 1Q CY2025.

Keep reading...Show less

Latest Press Releases

Related News

×